Actavia Life Sciences, Inc.
RASP · OTC
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $1 |
| SG&A Expenses | $0 | $0 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $4 | $0 | $0 | $0 |
| Operating Expenses | $4 | $0 | $0 | $1 |
| Operating Income | -$4 | $0 | -$0 | -$5 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | -$1 | -$1 | $0 |
| Pre-Tax Income | -$4 | -$1 | -$1 | -$5 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$4 | -$1 | -$1 | -$5 |
| % Margin | – | – | – | – |
| EPS | -0.008 | -0.01 | -0.013 | -0.078 |
| % Growth | 23% | 21.3% | 83.6% | – |
| EPS Diluted | -0.008 | -0.006 | -0.013 | -0.078 |
| Weighted Avg Shares Out | 578 | 69 | 69 | 69 |
| Weighted Avg Shares Out Dil | 578 | 111 | 69 | 69 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $1 | $0 |
| Depreciation & Amortization | $4 | $0 | $0 | $0 |
| EBITDA | -$0 | $0 | -$0 | -$1 |
| % Margin | – | – | – | – |